Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 6/20 | 0.38 |
| ▸ | NRP1 | O14786 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982779 | 0.84 | METAP2 (0.58) | TDP1LMNAMETAP2KDM4ETRIM24 | |
| SCHEMBL3979185 | 0.84 | KMT2A (0.42) | LMNAMETAP2KDM4E | |
| SCHEMBL3981242 | 0.78 | TDP1 (0.54) | TDP1LMNAMETAP2KDM4ECYP17A1 | |
| SCHEMBL3979202 | 0.76 | METAP2 (0.58) | METAP2CYP17A1 | |
| SCHEMBL3982442 | 0.75 | METAP2 (0.56) | TDP1METAP2 | |
| SCHEMBL3987489 | 0.72 | METAP2 (0.71) | METAP2KDM4E | |
| SCHEMBL3978404 | 0.70 | METAP2 (0.48) | LMNAMETAP2KDM4E | |
| SCHEMBL3987189 | 0.68 | METAP2 (0.59) | LMNAMETAP2KDM4E | |
| SCHEMBL6213526 | 0.66 | KDM4E (0.40) | LMNAMETAP2KDM4ETRIM24 | |
| SCHEMBL13359253 | 0.65 | LMNA (0.49) | TDP1LMNANLRP3KDM4ECYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | TDP1 3481/4885LMNA 4741/4885NLRP3 4337/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | TDP1 3481/4885LMNA 4741/4885NLRP3 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.